Lowering LDL--Not Only How Low, But How Long?
- 24 March 2006
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 311 (5768) , 1721-1723
- https://doi.org/10.1126/science.1125884
Abstract
People with a mutation in a proteolytic enzyme are at a substantially lower risk for coronary heart disease because of their lifelong reduction of plasma low-density lipoprotein.Keywords
This publication has 23 references indexed in Scilit:
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9Proceedings of the National Academy of Sciences, 2005
- Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse LiverJournal of Biological Chemistry, 2004
- Update on Statins: 2003Circulation, 2004
- Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotypeProceedings of the National Academy of Sciences, 2004
- Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed miceJournal of Lipid Research, 2003
- Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genesProceedings of the National Academy of Sciences, 2003
- Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ, 2003
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.BMJ, 1991